

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61B 5/0484	A1	(11) International Publication Number: WO 99/59469 (43) International Publication Date: 25 November 1999 (25.11.99)
<p>(21) International Application Number: PCT/AU99/00365</p> <p>(22) International Filing Date: 14 May 1999 (14.05.99)</p> <p>(30) Priority Data: PP 3547 15 May 1998 (15.05.98) AU</p> <p>(71) Applicant (for all designated States except US): SWINBURNE LIMITED [AU/AU]; John Street, Hawthorn, VIC 3122 (AU).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): SILBERSTEIN, Richard, Bernard [AU/AU]; 34 Jeffery Street, Blackburn, VIC 3130 (AU).</p> <p>(74) Agents: PRYOR, Geoffrey, Charles et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: DECENTRALISED PATIENT MANAGEMENT SYSTEM</p> <p>(57) Abstract</p> <p>A system (2) for evaluating the efficiency of therapeutic treatments of patients (40) located at remote sites (6) by communicating a cognitive task to the remote site via a network (10) which provides two-way communication between a central analysis site and the remote sites, presenting the task to the patient before, during, or after carrying out a therapeutic intervention or treatment, detecting brain response from the patient, and communicating this response to the central analysis site via the network.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DECENTRALISED PATIENT MANAGEMENT SYSTEM

5

The present invention relates to a decentralised patient management system. The invention also relates to a method of evaluating the efficacy of therapeutic intervention in a patient by assessment of different steady state visually evoked potentials.

10 United States Patent Nos. 4,955,938 and 5,331,969 (the contents of which are hereby incorporated herein by reference) disclose techniques for obtaining a steady state visually evoked potential (SSVEP) from a patient. These patents disclose the use of Fourier analysis in order to rapidly obtain the SSVEP's and changes thereto. It has now been appreciated that those techniques can be utilised to monitor the efficacy of treatment of patients. In one
15 embodiment patients are located at one or more remote sites and the SSVEP signals are sent to a central analysis site for processing. The central analysis site reports back to the remote site where the medical practitioner, psychiatrist or the like can receive a report on the likely suitability of a particular treatment for the patient. By using standard communications techniques and the Internet the remote sites can be established with relatively inexpensive
20 hardware and software, but have access to the more sophisticated analysis system located at the central analysis site.

In another embodiment, the efficacy of a therapeutic intervention or treatment can be made by assessing the differences between SSVEP's of a patient before and during the
25 application of a treatment or intervention.

According to the present invention there is provided a system for evaluating the efficacy of therapeutic treatments of patients located at remote sites, the system including:

- a central analysis site;
- 30 a plurality of remote test sites;
- input means at the central analysis site for inputting signals representative of a

- 2 -

cognitive task;

means for communicating the input signals to selected remote test sites via a network which provides two-way communication between the central analysis site and the remote sites;

receiving means at the remote test sites for receiving the input signals and presenting
5 the cognitive task to a patient (i) before and (ii) during or after carrying out a therapeutic intervention or treatment;

detecting means at the remote test sites for detecting brain response signals from the patient to said cognitive tasks;

means for communicating said brain response signals to said central analysis site via
10 the network; and

processing means for assessing the efficacy of the therapeutic intervention or treatment on the basis of differences in brain response signals before and during or after carrying out the therapeutic intervention or treatment.

15 The invention also provides a method of evaluating the efficacy of therapeutic intervention in a patient including the steps of recording a first steady state visually evoked potential (SSVEP) from the patient while undertaking a first cognitive task, carrying out a therapeutic intervention or treatment on the patient, recording a second steady state visually evoked potential (SSVEP) from the patient while undergoing a second cognitive task,
20 assessing the efficacy of the therapeutic intervention on the basis of differences between the first and second SSVEP's.

Preferably the first and second cognitive tasks are similar or the same.

25 Preferably the therapeutic intervention or treatment is for the purpose of treating neuropsychiatric disorders.

Preferably the step of carrying out the therapeutic intervention includes the step of administering a test dose of a psychotropic medication.

30

- 3 -

The psychotropic medication may comprise all chemical compounds or combination of chemical compounds used in the treatment of psychiatric, psychological, behavioural, educational or neurological disorders.

- 5 Preferably the step of assessing the efficacy includes the steps of detecting changes associated with therapeutic intervention in the SSVEP amplitude and/or phase topography and/or inter-electrode SSVEP coherence.

- 10 The invention also provides a method of evaluating the efficacy of therapeutic treatments of patients located at remote sites, the method including the steps of:
- causing a patient to carry out a first cognitive task at a remote site;
 - obtaining first signals representing the response of the patient's brain to said cognitive task;
 - carrying out a therapeutic treatment on the patient;
 - 15 obtaining second signals representing the response of the patient's brain to a second cognitive task whilst under the influence of said treatment;
 - transmitting the first signals and the second signals to a central analysis site;
 - analysing the first and second signals at the central analysis site to assess the efficacy of the therapeutic treatment; and
 - 20 transmitting the results of the assessment to the remote site.

Preferably the first and second signals are steady state visually evoked potentials (SSVEP's).

- 25 The invention also provides a system for evaluating the efficacy of therapeutic treatments of patients located at remote sites, the system including:
- a central analysis site;
 - input means for inputting signals representative of a cognitive task;
 - means for communicating the input signals to selected remote test sites via a network
 - 30 which provides two-way communication between the central analysis site and the remote sites for transmission of said signals to selected remote sites for presentation to a patient (i) before

- 4 -

and (ii) during or after carrying out a therapeutic intervention or treatment;

means for receiving said brain response signals of the patients transmitted to said central analysis site via the network; and

processing means for assessing the efficacy of the therapeutic intervention or treatment
5 on the basis of differences in brain response signals before and during or after carrying out the therapeutic intervention or treatment.

The invention also provides a method of evaluating the efficacy of therapeutic intervention in a patient including the steps of:

10 obtaining data representing a first steady state visually evoked potential (SSVEP) from a patient at a remote site while undertaking a first cognitive task;

obtaining data representing a second steady state visually evoked potential (SSVEP) from the patient while undergoing a second cognitive task during or after a therapeutic intervention; and

15 assessing the efficacy of the therapeutic intervention on the basis of differences between the first and second SSVEP's.

The invention also provides a test site for evaluation of the efficacy of a therapeutic treatment of a patient, the test site including:

20 receiving means for receiving input signals via a network from a central analysis site, said signals being representative of cognitive tasks;

presenting means for presenting the cognitive task to the patient (i) before and (ii) during or after carrying out a therapeutic intervention or treatment;

detecting means for detecting brain response signals from the patient to said cognitive
25 tasks; and

means for communicating said brain response signals obtained before and during or after carrying out a therapeutic intervention or treatment to said central analysis site via the network.

30 The invention also provides a method of evaluating the efficacy of therapeutic treatments of a patient located at a test site, the method including the steps of:

- 5 -

causing a patient to carry out a first cognitive task at the test site;
obtaining first signals representing the response of the patient's brain to said cognitive task;
carrying out a therapeutic intervention or treatment on the patient;
5 obtaining second signals representing the response of the patient's brain to a second cognitive task whilst under the influence of said treatment;
transmitting the first signals and the second signals to a central analysis site via a network wherein the first and second signals are analysed to assess the efficacy of the therapeutic treatment; and
10 receiving at the test site output signals from the central analysis site which demonstrate the efficacy of the therapeutic intervention or treatment on the patient.

The invention will now be further described with reference to the accompanying drawings, in which:

15 Figure 1 is a block diagram of a decentralised patient management system of the invention;

Figure 2 is a block diagram of a central analysis site;

Figure 3 is a block diagram for a remote site;

Figure 4 is a schematic block diagram for part of the hardware at a remote site;

20 Figure 5 is a schematic plan view showing input of signals to the eyes of a patient;

Figure 6 shows the use of a partial mirror to combine signals to the eye of a patient;

Figures 7, 8 and 9 are schematic views of LED shielding cages;

Figure 10 is a schematic block diagram of part of the hardware at a remote site;

Figure 11 shows part of an LED drive circuit;

25 Figure 12 shows a circuit for detecting ambient light levels;

Figure 13 shows in more detail circuitry for driving the LED array;

Figure 14 shows the LED array luminance as a function of input voltage; and

Figures 15 and 16 show typical changes in SSVEP in response to medication.

30 Figure 1 diagrammatically shows a decentralised patient management system 2 of the invention. It comprises a central analysis site 4 coupled to a plurality of remote test sites 6

- 6 -

by means of a network 8. The network 8 preferably comprises the Internet 10. The central analysis site 4 is coupled to the Internet by means of a high speed digital link 12 and each of the test sites 6 is connected to the Internet 10 by a modem 14 in the usual way.

5 The central analysis site 4 is shown in more detail in Figure 2. It comprises a central computer network 16 which is coupled for two-way communication to the link 12. The network 16 preferably comprises an array of computers which are linked together to achieve the computing power necessary to process multimedia material as well as analysing the large amount of EEG data from patents at the remote sites. Additionally, the network includes
10 appropriate hardware and software to handle various forms of the cognitive tasks to be presented to patients. The cognitive tasks are selected to probe various aspects of brain function such as attention, recognition memory, working memory, cognitive flexibility, perceptual-motor function, the perception of emotion and the experience of emotion.

15 The network 16 is coupled to output devices 18 such as printers and/or video recorders or the like. The network 16 may be coupled to a number of input devices 24 such as video and/or audio input devices for receiving material to be presented to patients. The computer network 16 may be coupled to an archival mass storage system 26 for electronic storage of inputs and signals received from the remote sites. The central analysis site may include
20 various output devices 28 including a printer, video recorder for producing video output.

The computer network 16 includes programs which utilise Fourier analysis to produce the changes in steady state response of the brain of a patient when the time varying cognitive task stimulus is presented to the patient. These techniques are disclosed in the
25 aforementioned United States patents and therefore need not be described in detail. Alternatively, analog or hybrid circuitry may be provided at the central analysis site for detection of the required signals, again in accordance with the principles disclosed in the aforementioned patents.

- 7 -

In summary, the central analysis site 4 performs a number of functions including:

- (i) receiving material to be presented to patients,
- (ii) producing digital cognited tasks which may be in the form of multimedia test material,
- (iii) downloading test sequences to specific patients,
- (iv) uploading brain electrical activity information from patients,
- (v) verifying patient state and quality of data,
- (vi) analysing brain activity, and
- (vii) producing reports in written and/or graphical form.

The remote sites 6 would normally be an appropriate medical establishment such as a hospital, clinic, psychiatrist's room or general practitioner's room. The electrical brain activity of the patient is recorded at the site and signals representative of this activity together with appropriate information on the cognitive task will be transferred to a central analysis site 4 via the Internet (or some other appropriate medium). The central analysis site 4 analyses the brain electrical activity and generates topographic maps of SSVEP amplitude and phase.

A typical session may involve testing a prospective patient's response to an anxiolytic (anxiety reducing) agent. The patient will undertake a cognitive task and steady state probe topography (SSPT) recording prior to and a predetermined time, say two hours, after the administration of a test dose of the proposed medication. Brain activity before and after drug administration are compared and the clinician is advised from reports from the central analysis site 4 as to whether the patient is likely to benefit from long term administration of the medication and the possibility of side-effects.

Patient progress may also be monitored during a course of the drug with the SSPT methodology and decisions on variations in dosage levels as well as discontinuation of treatment may be made more efficiently.

- 8 -

A typical medical consultation utilising the system of the invention typically includes the following steps:

1. A patient consults a psychiatrist, clinical psychologist or other medical practitioner at the local site 6 about, say, a mood disorder or possible depression.
2. The medical practitioner establishes a preliminary diagnosis of depression and wishes to ascertain the most effective drug treatment.
3. The patient is asked to move to the recording site in a test room at the local site 6 where he or she is fitted with a multi-electrode helmet 38 or another multi-electrode system such as Electro-cap (ECI Inc., Eaton, Ohio, USA) as described below. The fitting is done by either a nurse or a technician. The helmet 38 or multi-electrode system is connected to a data acquisition system and computer as described in more detail below.
4. The nurse or technician logs onto the central analysis site 4 via the Internet and downloads software for the relevant cognitive activation task. Preferably, the download is automatic and controlled by the central analysis site 4. Preferably the nurse or technician need only stipulate the type of psychiatric disorder under consideration.
5. The patient undertakes the cognitive activation task while SSPT recording takes place.
6. Brain electrical activity together with timing information on the cognitive task and the visual stimulus is encrypted and transmitted to the central analysis site 4.
7. Animated maps of the SSVEP amplitude and phase are generated at the central analysis site 4.
8. The patient is given a test dose of the selected medication and waits until plasma or brain levels have peaked. This is typically a period of from 1 to 2 hours.

- 9 -

9. Steps 5, 6 and 7 are then repeated.
10. Software at the central analysis site 4 analyses the SSVEP data and determines the differences between the first and second recording sessions. These differences are presented as animated brain maps and down-loaded to the remote site 6. In addition, a report may be generated which evaluates the likely long term patient response to the test medication.
11. The clinician considers the graphical data available along with the report and decides whether to test another agent or not. Testing of another agent would need to take place after the original test medication had been cleared from the body.

A similar approach could be used for ongoing monitoring of patient treatment.

- 15 The central analysis site 4 may utilise communication software and appropriate communications hardware to receive data from the remote sites 6 such as packages which are commercially available and therefore need not be described in detail. An example would be WS FTP32 or Cute FTP.

- 20 Brain electrical activity together with specific timing information on events in the test material is uploaded from the various test sites 6 as explained in more detail below.

- A typical test site 6 is shown in more detail in Figure 3. The test site 6 typically includes a computer 30 coupled to a monitor 32 or television set, keyboard 34 and mouse 36 or other pointing device. The computer 30 is coupled to the Internet 10 by means of the modem 14, as shown. The test site 6 includes the helmet 38 or other multi-electrode system which is arranged to pickup electrical brain activity of the patient 40, the helmet or other multi-electrode system being coupled to the computer 30 by means of a control and interface circuit 42.

- 10 -

The computer 30 preferably comprises a network computer or PC or the like which includes an additional, dedicated hard drive 44 which is used exclusively for the invention. The software required for display of test material to the patient 40 and for controlling transmission of brain activity signals to the central analysis site 4 is preferably stored on the
5 dedicated hard drive 44.

The helmet 38 includes a plurality of electrodes which can pickup brain activity of the patient 40. The helmet 38 includes a visor 46 through which the patient 40 can view the test material displayed on the monitor 32. The visor 46, however, provides for the display of a
10 continuous background flicker to the peripheral vision of the patient.

Signals representing electrical brain activity are detected by and recorded in the interface circuit 42. Generally speaking, the interface circuit 42 is arranged to filter and amplify the signals and then digitise and store the signals in an encrypted format.
15

Figure 5 schematically illustrates the optical components of the visor 46. The visor 46 includes two half-silvered mirrors 50 and 52 which enable the patient 40 to view the monitor 32 and also to receive the controlled background flicker. The background flicker is generated by means of first and second LED arrays 54 and 56 and is reflected towards the
20 eyes of the patient through the mirrors 50 and 52. Each LED array preferably comprises nine LED devices arranged in a three by three array and located in a double Faraday cage 58 for electrical shielding. A typical Faraday cage 58 is schematically illustrated in Figures 7, 8 and 9.

25 The luminance output of LED devices is not linear with respect to the applied voltage. Accordingly, in accordance with the invention, circuitry is provided to control the LED outputs so as to be linear. This is accomplished by using a feedback circuit 60 as shown in Figure 11. The circuit 60 includes a phototransistor 61 coupled to the negative input of an operational amplifier 62. The phototransistor 61 is arranged to receive output from one or
30 other of the LED arrays 54 and 56 or a further LED device connected thereto. The circuit 60 provides feedback for an LED drive circuit 64, as shown in Figure 4. One circuit

- 11 -

realisation for the LED drive circuit 64 is shown in Figure 13. The drive circuit 64 includes an input 66 which receives input signals from a microprocessor controller 68 via a digital to analog converter 69. The input signals are amplified in amplifier stages 70, 72 and 74, the feedback circuit 60 provides negative feedback for the stages 72 and 74, as shown. The LED drive circuit 64 thus is able to produce a linear luminance output from the LED arrays 54 and 56, over a reasonable range of voltages applied to the input 66. This is graphically illustrated in Figure 14 where the X-axis represents input voltage on the input 66 and the Y-axis represents luminance from the array 54 or 56. As indicated, the output luminance line 76 is substantially linear from about 0 volts to about 4 volts. Preferably, the LED flicker signals have a sinusoidal waveform.

The digital to analog converter 69 will produce the sinusoidal waveform when the microprocessor controller 68 sends the sine wave data held in a sine look-up table LUT stored in read only memory 100. A software counter will be used as a pointer to the sine wave LUT used to construct the sine wave. The output frequency of the waveform generator will be equal to the interrupting clock frequency divided by the number of digitised points 256 in the sine wave LUT incorporated in the program. The total harmonic distortion for a 256 point sine wave will be 0.71%. The reconstructed sine waves are then low-pass filtered by a suitable filter circuit provided in the LED drive circuit 64 to reduce the quantisation in the digitised waveforms and so reduce the total harmonic distortion.

The helmet 38 may be similar in appearance to a bicycle helmet and is used to house electrodes 82 for sensing brain electrical activity (EEG) and preferably has a single cable 84 connected to the rear of the helmet and extends to the circuit 42. The electrodes 82 are buffered by very high impedance unity gain amplifiers 86, as shown in Figure 4. The electrodes are located at predetermined positions in the helmet or other multi-electrode system.

Each of the amplifiers 86 provides a unity gain (non-inverting) with very low input bias current (1nA), very low noise (0.23uV) and additional gain is provided by very high input impedance (400 Gohm) amplifiers 87. Electrode impedance may be estimated by

- 12 -

injecting a very small current at the electrode site through a large resistance. The electrode impedance can then be estimated as it will form one arm of a potential divider. The outputs from the amplifiers 86 are coupled to sample and hold circuits 88 via filter circuits 90 which provide band pass filtering. The band limited instrumentation amplifier will be followed by
5 more gain and a very steep high cut-off switched filter. The switched filter will feed a two stage high cut filter (used to remove and clock feed through from the switched filter) then to the sample and hold circuits 88. The outputs of the sample and hold circuits 88 are connected to an analog multiplexer 91 and 16 bit analog to digital converter 92. The recorded EEG will normally be digitised to 16 bit accuracy. A 16 bit dynamic range means that the analog front-
10 end gain can be fixed at a predetermined value for typical patients. As the analog multiplexer 91 is fed by individual sample and hold circuits 88 (one per EEG channel) no data time skewing will occur. All EEG data and other relevant timing information will be stored in the hard drive 44. The computer then uploads this data to the central analysis site 4.

15 In order to maximise patient comfort, the brightness of the visual flicker is preferably slowly increased to its final value over a period of minutes.

The visor may include a light detector 48 for detecting ambient light levels, the detector 48 being coupled to an ambient light level detector circuit 43, an example of which
20 is shown in Figure 12. The circuit 43 converts the ambient light level to a voltage signal which is coupled by an amplifier, low pass filter 93, and sample and hold circuit 95 to the multiplexer 91, as shown in Figure 4. Voltage signals from the phototransistor 43 pass through the convertor 92 and are inputted to the microprocessor 68. The voltage drive from the phototransistor 43 is linearly proportional to the ambient light brightness. This voltage
25 will be measured by software in the microprocessor to give a brightness value. If the brightness value is too high, ambient light levels are too high and a message will be generated to advise the clinician to reduce the ambient light levels.

The microprocessor 68 also controls the acquisition of data by signalling the analog
30 to digital converter 92 to measure the current EEG value at an electrode 82, as determined by the microprocessor. This data will be stored in the S-RAM 94. The microprocessor with

- 13 -

the front-end amplifiers preferably include several high accuracy 32 bit counter/timers capture circuits 102. These 32 bit counter/timers capture circuits 102 generate the timing signals for data acquisition, visual flicker frequency as well as specific events in the material being presented to the patient. Such events may include the beginning and end of task sequences
5 as well as the timing of specific events. The timing data held in counters 102 can be captured when signalled by the above mentioned events. The captured timing data can be stored along with the recorded EEG data in the hard drive 44 and for later transmission and analysis. Software at test site may also detect any possible development of photo-epilepsy by monitoring the amplitude of the EEG at the flicker stimulus frequency. In the event of any
10 photo-epilepsy being detected, the flicker stimulus will be discontinued and the test terminated.

At the end of data acquisition, the data is encrypted and transferred to the central analysis site 4.

15

Cognitive tasks can be presented at the test site by using in-house software such as "PIPScript" or commercial software such as CANTAB or Ulead Media Studio. It will be appreciated by those skilled in the art that commercially available software packages can be utilised to perform the file storage and transfer functions required in carrying out the
20 techniques of the invention. Standard Internet communication software such as WS FTP32 or Cute FTP can be used to download multimedia files. These files can be compressed and encrypted using software such as WINZIP. Transfer of encrypted brain activity data can be transferred to the central analysis site 4 via FTP.

25 The CPU 16 may comprise a Silicon Graphics workstation or WIntel based system. A high security computer network fire-wall can be installed to reduce the risks of malicious hacking in accordance with known practice.

Preferably the material which constitutes the cognitive task as well as brain electrical
30 activity is held in the storage device 26 for ongoing access. Also, archival storage may be provided and a very high capacity tape system (at least 10,000 gigabyte) is preferred.

Archiving may be done using Digital Video Disk (DVD) media.

Software in the CPU 16 calculates Steady State Visually Evoked Potential (SSVEP) amplitude and phase for each stimulus cycle. The SSVEPC refers to the mean coherence over the entire duration of a cognitive task while the ER-SSVEPC refers to the changes in coherence over the duration of a typical trial in a cognitive task. Calculation accomplished used Fourier techniques using equations 1.0 and 1.1.

$$a_n = \frac{1}{S\Delta\tau} \sum_{i=0}^{S-1} f(nT + i\Delta\tau) \cos\left(\frac{2\pi}{T}(nT + i\Delta\tau)\right)$$

$$b_n = \frac{1}{S\Delta\tau} \sum_{i=0}^{S-1} f(nT + i\Delta\tau) \sin\left(\frac{2\pi}{T}(nT + i\Delta\tau)\right) \quad 1.0$$

Calculation of SSVEP Fourier components where a_n and b_n are the cosine and sine Fourier coefficients respectively. n represents the n^{th} stimulus cycle, S is the number of samples per stimulus cycle (16), $\Delta\tau$ is the time interval between samples, T is the period of one cycle and $f(nT + i\Delta\tau)$ is the EEG signal.

$$SSVEP_{\text{amplitude}} = \sqrt{(a_n^2 + b_n^2)}$$

$$SSVEP_{\text{phase}} = \arctan\left(\frac{b_n}{a_n}\right) \quad 1.1$$

Calculation of SSVEP amplitude and phase where a_n and b_n are the cosine and sine Fourier coefficients respectively. Amplitude and phase components can be calculated using either single cycle Fourier coefficients or coefficients that have been calculated by integrating across multiple cycles.

- 15 -

In addition to SSVEP amplitude and phase changes associated with the therapeutic intervention, it is also possible to determine the therapeutic intervention induced changes in the relationship between the SSVEP at different electrodes by measuring the *coherence*. The coherence is similar to the correlation coefficient expressed as a function of frequency.

5

Two types of coherence functions are calculated from the SSVEP sine and cosine Fourier coefficients while patients undertake the cognitive task. One will be termed the *SSVEP Coherence (SSVEPC)* and the other, *Event Related SSVEP Coherence (ER-SSVEPC)*.

10 SSVEPC

The SSVEP sine and cosine coefficients can be expressed as complex numbers

$$C_n = (a_n, b_n) \quad 1.2$$

where a_n and b_n have been previously defined.

15 The nomenclature is generalised to take into account multiple tasks and multiple electrodes.

$$C_{g,e,n} = (a_{g,e,n}, b_{g,e,n}) \quad 1.3$$

where g = the task number

e = the electrode

n = the point in time

20

- 16 -

Relevant functions can be defined by the following equations:

$$\gamma_{g,e1,e2} = H_{g,e1,e2} / T_{g,e1,e2} \quad 1.4$$

$$H_{g,e1,e2} = \sum_{n=1}^{n=T} C_{g,e1,n} \cdot C_{g,e2,n}^* \quad 1.5$$

and

$$T_{g,e1,e2} = \sqrt{\left(\sum_{n=1}^T C_{g,e1,n} \cdot C_{g,e1,n}^* \right) \left(\sum_{n=1}^T C_{g,e2,n} \cdot C_{g,e2,n}^* \right)} \quad 1.6$$

The SSVEPC coherence is then given by

$$\gamma_{g,e1,e2}^2 = |H_{g,e1,e2}|^2 / T_{g,e1,e2}^2 \quad 1.7$$

5 And the phase of the SSVEPC is given by

$$\Phi_{g,e1,e2} = \tan^{-1} \left(\frac{\text{Im}(H_{g,e1,e2})}{\text{Re}(H_{g,e1,e2})} \right) \quad 1.8$$

ERSSVEP-C

In this case, the coherence across trials in a particular task are calculated. This yields coherence as a function of time. We generalise the nomenclature to take into account multiple
10 tasks and multiple electrodes.

$$C_{g,d,e,n} = (a_{g,d,e,n}, b_{g,d,e,n}) \quad 1.9$$

- 17 -

where g = the task number

d = the trial within a particular task, e.g. a specific response

e = the electrode

n = the point in time

5

Relevant functions can be defined by the following equations:

$$\gamma_{g,e1,e2,n} = H_{g,e1,e2,n} / T_{g,e1,e2,n} \quad 1.10$$

$$H_{g,e1,e2,n} = \sum_{d=1}^{d=D} C_{g,e1,d,n} \cdot C_{g,e2,d,n}^* \quad 1.11$$

and

$$T_{g,e1,e2,n} = \sqrt{\left(\sum_{d=1}^D C_{g,e1,d,n} \cdot C_{g,e1,d,n}^* \right) \left(\sum_{d=1}^D C_{g,e2,d,n} \cdot C_{g,e2,d,n}^* \right)} \quad 1.12$$

The SSVEPC is then given by

$$\gamma^2_{g,e1,e2,n} = |H_{g,e1,e2,n}|^2 / T^2_{g,e1,e2,n} \quad 1.13$$

And the phase of the SSVEPC is given by

$$\Phi_{g,e1,e2,n} = \tan^{-1} \left(\frac{\text{Im}(H_{g,e1,e2,n})}{\text{Re}(H_{g,e1,e2,n})} \right) \quad 1.14$$

10

The step of assessing the efficacy includes the steps of detecting changes associated with therapeutic intervention in the SSVEP amplitude and/or phase topography.

- 18 -

Precise timing on the various events is supplied by the encrypted data file uploaded from patients.

Information about brain activity and brain speed of processing is preferably available
5 for each of the recording sites. Preferably there are about sixty-four scalp recording sites.

The CPU 16 may also run software for producing written reports outlining the response of the patient's brain to the test therapeutical treatment. The clinician administering the test treatment can then decide on the suitability of continued administration of the
10 therapeutical treatment for the particular patient.

In summary, SSPT is to be used to evaluate therapeutic intervention in patients suffering from a wide range of neuropsychiatric disorders including, but not limited to, disorders of mood, anxiety disorders, neurodegenerative disorders (e.g. Alzheimer's
15 dementia), disorders of attention, cognition and impulse control. Patients will be required to perform a number of specified cognitive tasks before and after therapeutic intervention. The steady state visually evoked potential (SSVEP) will be recorded from (typically) 64 scalp sites while patients undertake the cognitive tasks.

20 Changes in the SSVEP amplitude and phase topography are used to ascertain the effectiveness of the therapeutic intervention. For example, the short term (2 hours) response to a dose of psychotropic medication (eg a neurostimulant or an antidepressant) may be used to predict the long term responsiveness to such medication. The clinician may then use the SSPT technology to select the most effective medication regimen (such as selection of drug,
25 dosage and optimum treatment duration).

Example 1

An example of the invention will now be briefly described with reference to Figures
30 15 and 16. The method was used on patients who are children diagnosed with Attention Deficit Hypoactivity Disorder (ADHD).

- 19 -

Children diagnosed with ADHD were tested to examine the effects of stimulant medication (methylphenidate or Ritalin) on the amplitude and phase of the steady state visually evoked potential (SSVEP). The children performed two cognitive tasks before the stimulant medication was administered and then repeat the tasks one hour after stimulant medication was
5 administered.

The first task was a low demand vigilance task where the patients were required to press a micro switch on the predictable appearance of the number "5" in the repeated sequence "1, 2, 3, 4, 5". The second task was known as the A-X version of the Continuous
10 Performance Task (CPT A-X). In this more demanding task, patients were required to press a micro switch on the appearance of the letter "X" if and only if it has been preceded by the letter "A".

Figures 15 and 16 illustrate the spatial distribution of the difference between the mean
15 SSVEP phase, evaluated over the entire CPT A-X task before medication, and the point in time corresponding to the disappearance of the letter "A" in the CPT A-X task after medication.

More particularly, Figure 15 shows changes in SSVEP phase during the performance
20 of the Continuous Performance Task in a 12 year old boy diagnosed with ADHD and responding to the stimulant medication. Scalp distribution of SSVEP latency is viewed from the top of the head. The uppermost portion of map illustrates activity in frontal brain sites while the bottom corresponds to the back (occipital lobe) of the head. Light areas are associated with SSVEP phase advance (latency reduction), grey areas illustrate regions of
25 SSVEP latency increase. Contours correspond to latency changes of 6 msec. The presence of large SSVEP latency reduction at prefrontal sites predicts a good long term clinical response to the stimulant medication for the patient.

In contrast, Figure 16 shows changes in SSVEP phase during the performance of the
30 Continuous Performance Task in a different 12 year old boy diagnosed with ADHD and not responding to stimulant medication. The absence of SSVEP latency reduction at prefrontal

- 20 -

sites predicts a poor long term clinical response to the stimulant medication for the patient.

In summary, the spatial distribution shown in Figure 15 shows a strong reduction in the SSVEP latency at prefrontal scalp sites which suggests a normalisation of brain activity
5 during this task. It is suggested that such a response is indicative of a positive long-term response to stimulant medication. By contrast, the spatial distribution illustrated in Figure 16 shows little or no latency reduction at prefrontal sites. This result suggests that there would be a poor response in that patient to stimulant medication.

10 Many modifications will be apparent to those skilled in the art without departing from the spirit and scope of the invention.

- 21 -

CLAIMS:

1. A system (2) for evaluating the efficacy of therapeutic treatments of patients (40) located at remote sites (6), the system including:
 - 5 a central analysis site (4);
 - a plurality of remote test sites (6);
 - input means (24) at the central analysis site for inputting signals representative of a cognitive task;
 - means for communicating the input signals (12) to selected remote test sites via a
10 network (10) which provides two-way communication between the central analysis site and the remote sites;
 - receiving means (14,30,44) at the remote test sites for receiving the input signals and presenting the cognitive task to a patient (40) (i) before and (ii) during or after carrying out a therapeutic intervention or treatment;
 - 15 detecting means (38,42) at the remote test sites for detecting brain response signals from the patient to said cognitive tasks;
 - means for communicating (14) said brain response signals to said central analysis site via the network; and
 - processing means (16) for assessing the efficacy of the therapeutic intervention or
20 treatment on the basis of differences in brain response signals before and during or after carrying out the therapeutic intervention or treatment.
2. A system as claimed in claim 1 wherein the remote sites include storage devices (44) for storage of signals representing said cognitive task.
- 25 3. A system as claimed in claim 1 or 2 wherein the processing means (16) includes means for calculating amplitude and phase steady state visually evoked potentials (SSVEP) for each site where a patient is treated.
- 30 4. A system as claimed in claim 3 wherein the processing means includes means for detecting changes attributable to the therapeutic intervention or treatment in SSVEP amplitude

- 22 -

and/or phase topography.

5. A system as claimed in claim 3 or 4 wherein the detecting means (38) includes a plurality of electrodes on which said brain response signals are received and the processing
5 means includes means for detecting changes attributable to the therapeutic intervention or treatment in inter-electrode SSVEP coherence.

6. A system as claimed in claim 4 or 5 wherein processing means produces output signals which represent animated brain maps.

10

7. A system as claimed in claim 6 wherein said means for communication transmits said output signals to the remote site from which said output signals were derived for presentation to a clinician.

15 8. A system as claimed in claim 7 wherein the remote site includes display means for display of said output signals as animated brain maps.

9. A method of evaluating the efficacy of therapeutic intervention in a patient (10) including the steps of recording a first steady state visually evoked potential (SSVEP) from
20 the patient while undertaking a first cognitive task, carrying out a therapeutic intervention or treatment on the patient, recording a second steady state visually evoked potential (SSVEP) from the patient while undergoing a second cognitive task, assessing the efficacy of the therapeutic intervention on the basis of differences between the first and second SSVEP's.

25 10. A method as claimed in claim 9 wherein the first and second cognitive tasks are similar or the same.

11. A method as claimed in claim 10 wherein the therapeutic intervention or treatment is for the purpose of treating neuropsychiatric disorders.

30

- 23 -

12. A method as claimed in claim 11 wherein the step of carrying out the therapeutic intervention includes the step of administering a test dose of a psychotropic medication.

13. A method as claimed in claim 12 wherein the psychotropic medication comprises a
5 chemical compound or compounds used in the treatment of psychiatric, psychological, behavioural, educational or neurological disorders.

14. A method as claimed in claim 13 wherein the step of assessing the efficacy includes the steps of detecting changes associated with therapeutic intervention in the SSVEP amplitude
10 and/or phase topography.

15. A method as claimed in claim 13 or 14 wherein the steps of obtaining first and second signals are effected by placing electrodes adjacent to the scalp of the patient, the first and second signals being produced on said electrodes and the step of assessing the efficacy
15 includes detecting changes in inter-electrode SSVEP coherence.

16. A method of evaluating the efficacy of therapeutic treatments of patients (40) located at remote sites (6), the method including the steps of:

- causing a patient to carry out a first cognitive task at a remote site;
- 20 obtaining first signals representing the response of the patient's brain to said cognitive task;
- carrying out a therapeutic treatment on the patient;
- obtaining second signals representing the response of the patient's brain to a second cognitive task whilst under the influence of said treatment;
- 25 transmitting the first signals and the second signals to a central analysis site (4);
- analysing the first and second signals at the central analysis site to assess the efficacy of the therapeutic treatment; and
- transmitting the results of the assessment to the remote site.

30 17. A system for evaluating the efficacy of therapeutic treatments of patients (40) located at remote sites, the system including:

- 24 -

a central analysis site (4);

input means (24) for inputting signals representative of a cognitive task;

means for communicating the input signals (12) to selected remote test sites via a network (10) which provides two-way communication between the central analysis site and the remote sites for transmission of said signals to selected remote sites for presentation to a patient (i) before and (ii) during or after carrying out a therapeutic intervention or treatment;

means (14) for receiving said brain response signals of the patients transmitted to said central analysis site via the network; and

processing means for assessing the efficacy of the therapeutic intervention or treatment on the basis of differences in brain response signals before and during or after carrying out the therapeutic intervention or treatment.

18. A system as claimed in claim 17 wherein the processing means (16) includes means for calculating amplitude and phase steady state visually evoked potentials (SSVEP) for each site where a patient is treated.

19. A system as claimed in claim 18 wherein the processing means includes means for detecting changes attributable to the therapeutic intervention or treatment in SSVEP amplitude and/or phase topography.

20

20. A system as claimed in claim 18 or 19 wherein processing means produces output signals which represent animated brain maps.

21. A system as claimed in claim 20 wherein said means for communication transmits said output signals to the remote site from which said output signals were derived.

22. A method of evaluating the efficacy of therapeutic intervention in a patient (4) including the steps of:

obtaining data representing a first steady state visually evoked potential (SSVEP) from a patient at a remote site (6) while undertaking a first cognitive task;

obtaining data representing a second steady state visually evoked potential (SSVEP)

- 25 -

from the patient while undergoing a second cognitive task during or after a therapeutic intervention; and

assessing the efficacy of the therapeutic intervention on the basis of differences between the first and second SSVEP's.

5

23. A method as claimed in claim 22 wherein the first and second cognitive tasks are similar or the same.

24. A test site (6) for evaluation of the efficacy of a therapeutic treatment of a patient (40),
10 the test site including:

receiving means (14,30,44) for receiving input signals via a network (10) from a central analysis site, said signals being representative of cognitive tasks;

presenting means for presenting the cognitive task to the patient (40) (i) before and (ii) during or after carrying out a therapeutic intervention or treatment;

15 detecting means (38,42) for detecting brain response signals from the patient to said cognitive tasks; and

means for communicating (14) said brain response signals obtained before and during or after carrying out a therapeutic intervention or treatment to said central analysis site via the network.

20

25. A test site as claimed in claim 24 wherein the receiving means includes:

a computer system (30) having a storage medium (44) which is dedicated to receiving signals from the central analysis site.

25 26. A test site as claimed in claim 25 wherein the detecting means includes an electrode helmet (38) coupled to an interface circuit (42) which digitises and stores brain response signals produced by said helmet.

27. A method of evaluating the efficacy of therapeutic treatments of a patient (40) located
30 at a test site, the method including the steps of:

causing a patient to carry out a first cognitive task at the test site;

- 26 -

obtaining first signals representing the response of the patient's brain to said cognitive task;

carrying out a therapeutic intervention or treatment on the patient;

obtaining second signals representing the response of the patient's brain to a second
5 cognitive task whilst under the influence of said treatment;

transmitting the first signals and the second signals to a central analysis site (4) via a network (10) wherein the first and second signals are analysed to assess the efficacy of the therapeutic treatment; and

receiving at the test site output signals from the central analysis site which demonstrate
10 the efficacy of the therapeutic intervention or treatment on the patient.

28. A method as claimed in claim 27 wherein the first and second cognitive tasks are similar or the same.


15 29. A method as claimed in claim 28 wherein the therapeutic intervention or treatment is for the purpose of treating neuropsychiatric disorders.

30. A method as claimed in claim 29 wherein the step of carrying out the therapeutic intervention includes the step of administering a test dose of a psychotropic medication.
20


31. A method as claimed in claim 30 wherein the psychotropic medication comprises a chemical compound or compounds used in the treatment of psychiatric, psychological, behavioural, educational or neurological disorders.

25 32. A method as claimed in claim 31 wherein the steps of obtaining first and second signals are effected by placing electrodes adjacent to the scalp of the patient, first and second signals being produced on said electrodes and the step of assessing the efficacy includes detecting changes in inter-electrode SSVEP coherence.


1/12




2/12



3/12

FIGURE 3A

4/12

FIGURE 3B






FIGURE 4

6/12

FIGURE 5FIGURE 6








FIGURE 7

8/12

FIGURE 8FIGURE 9FIGURE 10

9/12

FIGURE 11FIGURE 12





FIGURE 13

11/12

FIGURE 14




FIGURE 15




FIGURE 16

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00365

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁶: A61B 5/0484

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

ELECTRONIC SEARCH

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WPAT, JAPIO**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3880144 A (COURSIN et al.) 29 April 1975 See figure 1.	1 to 32
X	US 3892227 A (COURSIN et al.) 1 July 1975 See figure 1.	1 to 32
X	US 5357427 A (LANGEN et al.) 18 October 1994 See figures 1 and 2.	1 to 32

☒ Further documents are listed in the continuation of Box C☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
13 July 1999Date of mailing of the international search report
21 JUL 1999Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200
WODEN ACT 2606
AUSTRALIA
Facsimile No.: (02) 6285 3929

Authorized officer

PETER T. WEST
Telephone No.: (02) 6283 2108

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00365

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5730146 A (ITIL et al.) 24 March 1998 See figure 3.	1 to 32

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/AU 99/00365

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
US 3880144	US 3889227
US 3889227	US 3880144
US 5357427	NONE
US 5730146	NONE

END OF ANNEX

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 20 January 2000 (20.01.00)	
International application No. PCT/AU99/00365	Applicant's or agent's file reference 2178060/GP
International filing date (day/month/year) 14 May 1999 (14.05.99)	Priority date (day/month/year) 15 May 1998 (15.05.98)
Applicant SILBERSTEIN, Richard, Bernard	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

15 December 1999 (15.12.99)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer</p> <p>S. Mafla</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	---

16

PATENT COOPERATION TREATY
PCT
INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

REC'D 03 JUL 2000
WIPPO
PCT

Applicant's or agent's file reference 2178060	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).	
International application No. PCT/AU 99/00365	International filing date (day month year) 14 May 1999	Priority Date (day month year) 15 May 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl.⁷ A61B 5/0484		
Applicant SWINBURNE LIMITED; et al.		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																								
2.	<p>This REPORT consists of a total of 3 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 4 sheet(s).</p>																								
3.	<p>This report contains indications relating to the following items:</p> <table border="0"> <tr> <td>I</td> <td><input checked="" type="checkbox"/></td> <td>Basis of the report</td> </tr> <tr> <td>II</td> <td><input type="checkbox"/></td> <td>Priority</td> </tr> <tr> <td>III</td> <td><input type="checkbox"/></td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td><input type="checkbox"/></td> <td>Lack of unity of invention</td> </tr> <tr> <td>V</td> <td><input checked="" type="checkbox"/></td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td><input type="checkbox"/></td> <td>Certain documents cited</td> </tr> <tr> <td>VII</td> <td><input type="checkbox"/></td> <td>Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td><input type="checkbox"/></td> <td>Certain observations on the international application</td> </tr> </table>	I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																							
II	<input type="checkbox"/>	Priority																							
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
IV	<input type="checkbox"/>	Lack of unity of invention																							
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
VI	<input type="checkbox"/>	Certain documents cited																							
VII	<input type="checkbox"/>	Certain defects in the international application																							
VIII	<input type="checkbox"/>	Certain observations on the international application																							

Date of submission of the demand 15 December 1999	Date of completion of the report 18 May 2000
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer PETER T. WEST Telephone No. (02) 6283 2108

I. Basis of the report1 With regard to the **elements** of the international application *

- ☐ the international application as originally filed.
- ☒ the description, pages **1 to 20**, as originally filed.
pages , filed with the demand,
pages , received on with the letter of .
- ☒ the claims, pages , as originally filed.
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages **21 to 24**, received on **14 April 2000** with the letter of **14 April 2000**.
- ☒ the drawings, pages , as originally filed.
pages , filed with the demand,
pages **1 to 12**, received on **29 July 1999** with the letter of **27 July 1999**.
- ☐ the sequence listing part of the description:
pages , as originally filed
pages , filed with the demand
pages , received on with the letter of .

2 With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3 With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, was on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4 ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig

5 ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)). **

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims 1 to 21	YES
	Claims	NO
Inventive step (IS)	Claims 1 to 21	YES
	Claims	NO
Industrial applicability (IA)	Claims 1 to 21	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

The following documents identified in the International Search Report have been considered for the purposes of this report:

- D1 US 3880144 A (COURSIN et al) 29 April 1975
D2 US 3892227 A (COURSIN et al) 1 July 1975
D3 US 5357427 A (LANGREN et al) 18 October 1994
D4 US 5730146 A (ITIL et al) 24 March 1998

Novelty (N) and Inventive Step (IS)

Claims 1, 8, 15, 16 and 20 relate to a system for evaluating the efficacy of the therapeutic treatment of patients located at remote sites including processing means having means for calculating amplitude and/or phase steady state visually evoked potential (SSVEP) from brain response signals for each site where the patient is treated. Whilst some of the individual features of the claimed system are known from the prior art documents D1 to D4, none disclose or suggest the particular combination of features which is defined in claims 1, 8, 15, 16 or 20. In particular, none of these documents disclose or suggest assessing the efficacy of the therapeutic intervention at a remote site by computation of amplitude and/or phase SSVEP from patients located at remote sites.

Therefore the subject matter of these claims is new and the claim meets the requirements of Article 33(2) PCT with regard to the requirement for novelty.

The claimed invention is not obvious in the light of any of the cited documents nor disclosed in any obvious combination, nor would the claimed invention be obvious to a person skilled in the art in the light of common general knowledge by itself or in combination with any of these documents.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 2178060/GP/DR	<div style="display: flex; justify-content: space-between;"> <div style="text-align: center;">FOR FURTHER ACTION</div> <div>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below</div> </div>	
International application No. PCT/AU 99/00365	International filing date (<i>day month year</i>) 14 May 1999	(Earliest) Priority Date (<i>day month year</i>) 15 May 1998
Applicant SWINBURNE LIMITED		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (See Box II).

4. With regard to the **title**, ☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**, ☐ the text is approved as submitted by the applicant

☒ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III
The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority

6. The figure of the **drawings** to be published with the abstract is Figure No

☐ as suggested by the applicant.

☒ None of the figures

☐ because the applicant failed to suggest a figure

☐ because this figure better characterizes the invention

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

A system (2) for evaluating the efficiency of therapeutic treatments of patients (40) located at remote sites (6) by communicating a cognitive task to the remote site via a network (10) which provides two-way communication between a central analysis site and the remote sites, presenting the task to the patient before, during, or after carrying out a therapeutic intervention or treatment, detecting brain response from the patient, and communicating this response to the central analysis site via the network.

INTERNATIONAL SEARCH REPORT

International application No
PCT/AU 99/00365**A. CLASSIFICATION OF SUBJECT MATTER**Int Cl⁶: A61B 5/0484

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

ELECTRONIC SEARCH

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPAT, JAPIO

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	US 3880144 A (COURSIN et al.) 29 April 1975 See figure 1.	1 to 32
X	US 3892227 A (COURSIN et al.) 1 July 1975 See figure 1.	1 to 32
X	US 5357427 A (LANGEN et al.) 18 October 1994 See figures 1 and 2.	1 to 32

☒ Further documents are listed in the
continuation of Box C☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
13 July 1999Date of mailing of the international search report
21 JUL 1999Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200
WODEN ACT 2606
AUSTRALIA
Facsimile No (02) 6285 3929Authorized officer

PETER T. WEST
Telephone No (02) 6283 2108

INTERNATIONAL SEARCH REPORT

International application No

PCT/AU 99/00365

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5730146 A (ITIL et al.) 24 March 1998 See figure 3.	1 to 32

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/AU 99/00365

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
US 3880144	US 3889227
US 3889227	US 3880144
US 5357427	NONE
US 5730146	NONE

END OF ANNEX